Status:
RECRUITING
Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease
Lead Sponsor:
National Human Genome Research Institute (NHGRI)
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
2-99 years
Brief Summary
The purpose of this research study is to look at genes and determine how they interact with each other to find changes that could explain why some people's immune systems may respond to blood transfus...
Detailed Description
Study Description: This study seeks to fine-map risk variants associated with increased susceptibility to developing red blood cell alloantibodies in patients with sickle cell disease (SCD), with the...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA
- To be eligible to participate in this study, an individual must meet all of the following criteria:
- 1\. Individual (\> 2 years of age) with confirmed SCD diagnosis who meets at least one of the following conditions:
- History of greater than ten administered transfusions or 20 transfusion units (where known)
- History of one or more antibody screens
- Known candidate variant genotype
- EXCLUSION CRITERIA
- An individual who meets any the following criteria will be excluded from participation in this study:
- Impaired decision-making capability, with or without a legally authorized representative
- History of transplant (e.g., organ, bone marrow, stem cell)
- Taking immunosuppressive medications at time of enrollment
- Confirmed pregnancy
Exclusion
Key Trial Info
Start Date :
June 24 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 10 2030
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06944067
Start Date
June 24 2025
End Date
April 10 2030
Last Update
June 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892